Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinomaTaizo Uchimoto, Haruhito Azuma, Yusuke Yano et al.|British Journal of Urology|2022Cited by 10
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Haruhito Azuma, Shuya Tsuchida et al.|Targeted Oncology|2024Cited by 9
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Haruhito Azuma, Takuya Higashio et al.|Oncology|2023Cited by 3
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial CarcinomaKyosuke Nishio, Kazumasa Komura, Kensuke Hirosuna et al.|Anticancer Research|2025Cited by 2